OMC Financial Services LTD Boosts Stock Holdings in Amgen Inc. $AMGN

Key Points

• OMC Financial Services LTD increased its stake in Amgen Inc. by 82.5% during the 2nd quarter, holding a total of 5,165 shares valued at approximately $1.44 million by the quarter's end.
• Amgen reported a Q2 earnings per share (EPS) of $6.02, surpassing analyst expectations of $5.28, with revenues reaching $9.18 billion and representing a 9.4% increase year-over-year.
• The company declared a quarterly dividend of $2.38 per share, yielding 3.2% annually, with a payout ratio of 77.84%.

OMC Financial Services LTD boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 82.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,165 shares of the medical research company's stock after acquiring an additional 2,335 shares during the period. OMC Financial Services LTD's holdings in Amgen were worth $1,442,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Fairvoy Private Wealth LLC lifted its position in Amgen by 1.1% during the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock valued at $885,000 after purchasing an additional 35 shares during the last quarter. Nicholson Wealth Management Group LLC lifted its holdings in shares of Amgen by 0.6% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock worth $1,652,000 after acquiring an additional 35 shares during the last quarter. Crumly & Associates Inc. lifted its holdings in shares of Amgen by 3.2% in the 2nd quarter. Crumly & Associates Inc. now owns 1,146 shares of the medical research company's stock worth $320,000 after acquiring an additional 36 shares during the last quarter. Maryland Capital Advisors Inc. lifted its holdings in shares of Amgen by 5.2% in the 2nd quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company's stock worth $204,000 after acquiring an additional 36 shares during the last quarter. Finally, Lion Street Advisors LLC lifted its holdings in shares of Amgen by 1.3% in the 2nd quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company's stock worth $774,000 after acquiring an additional 36 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 0.7%

NASDAQ AMGN opened at $301.14 on Wednesday. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The company has a market capitalization of $162.12 billion, a price-to-earnings ratio of 24.62, a price-to-earnings-growth ratio of 2.68 and a beta of 0.49. The company's 50-day simple moving average is $287.83 and its two-hundred day simple moving average is $287.15. Amgen Inc. has a one year low of $253.30 and a one year high of $335.88.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter last year, the firm posted $4.97 EPS. The company's revenue for the quarter was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were given a $2.38 dividend. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2%. Amgen's payout ratio is presently 77.84%.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares of the company's stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.69% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Piper Sandler raised their target price on shares of Amgen from $328.00 to $342.00 and gave the stock an "overweight" rating in a report on Monday, August 25th. Bank of America lifted their price objective on shares of Amgen from $261.00 to $272.00 and gave the company an "underperform" rating in a report on Friday, September 26th. Wall Street Zen upgraded shares of Amgen from a "hold" rating to a "buy" rating in a report on Sunday. UBS Group decreased their price objective on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a report on Wednesday, August 6th. Finally, Raymond James Financial began coverage on shares of Amgen in a report on Wednesday, September 3rd. They set a "market perform" rating for the company. Six research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $300.94.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.